China wants 5 innovative drugs with US$1 billion returns by 2030. Which might they be?
The increasing global appeal of Chinese firms’ novel therapies has propelled the country’s rise as a biomedical powerhouse, but China has yet to produce a drug to rival all-time best-selling Western blockbusters in sales.
Beijing has set ambitious new five-year targets to boost its global presence, including at least five products with annual global sales surpassing US$1 billion by 2030.
The goal is achievable, according to some analysts.
Jefferies’ head of Asia healthcare research Cui Cui noted...
此摘要由5News从媒体的公开信息源汇聚而成。 包含完整背景的全文在www.scmp.com — 内容归South China Morning Post - Business所有。
